MX2018008321A - Tratamiento de tumores ocasionados por disfuncion metabolica. - Google Patents
Tratamiento de tumores ocasionados por disfuncion metabolica.Info
- Publication number
- MX2018008321A MX2018008321A MX2018008321A MX2018008321A MX2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A MX 2018008321 A MX2018008321 A MX 2018008321A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- metabolic dysfunction
- tumors driven
- driven
- present disclosure
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000003818 metabolic dysfunction Effects 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277293P | 2016-01-11 | 2016-01-11 | |
| US201662393929P | 2016-09-13 | 2016-09-13 | |
| US201662395446P | 2016-09-16 | 2016-09-16 | |
| PCT/US2017/012968 WO2017123603A1 (en) | 2016-01-11 | 2017-01-11 | Treatment for tumors driven by metabolic dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008321A true MX2018008321A (es) | 2018-09-21 |
Family
ID=57882196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008321A MX2018008321A (es) | 2016-01-11 | 2017-01-11 | Tratamiento de tumores ocasionados por disfuncion metabolica. |
| MX2023002076A MX2023002076A (es) | 2016-01-11 | 2018-07-04 | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002076A MX2023002076A (es) | 2016-01-11 | 2018-07-04 | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10646463B2 (enExample) |
| EP (1) | EP3402529A1 (enExample) |
| JP (3) | JP7022066B2 (enExample) |
| KR (1) | KR20180100663A (enExample) |
| CN (2) | CN114225045B (enExample) |
| AU (3) | AU2017206718B2 (enExample) |
| CA (2) | CA3008960C (enExample) |
| MX (2) | MX2018008321A (enExample) |
| WO (1) | WO2017123603A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| US9173956B2 (en) | 2013-04-10 | 2015-11-03 | Syndevrx, Inc. | METAP2 inhibitors and methods of treating obesity |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
| CN107670048B (zh) | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| WO2020087077A1 (en) * | 2018-10-26 | 2020-04-30 | Syndevrx,Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| CN112915210B (zh) * | 2019-12-06 | 2024-08-20 | 重庆阿普格雷生物科技有限公司 | 一种聚乙二醇偶联药物、其制备方法及应用 |
| CN116887836A (zh) * | 2020-11-11 | 2023-10-13 | 辛德弗雷克斯公司 | 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合 |
| CA3198173A1 (en) * | 2020-11-11 | 2022-05-19 | Peter Cornelius | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
| JP2025526665A (ja) * | 2022-08-10 | 2025-08-15 | シンデブルックス，インコーポレイティド | 肺線維症の治療のためのｍｅｔａｐ２阻害剤 |
| KR20250117799A (ko) * | 2022-11-16 | 2025-08-05 | 신데브알엑스, 인크. | 전립선암의 치료를 위한 metap2 억제제 |
| CN119932197B (zh) * | 2025-04-09 | 2025-06-13 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 磷酸二酯酶6d作为前列腺癌用药指导标志物的应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2803586A (en) | 1953-06-29 | 1957-08-20 | Abbott Lab | ph control in production of fumagillin |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| WO1999011272A1 (en) | 1997-09-02 | 1999-03-11 | Johns Hopkins University School Of Medicine | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| WO1999039702A2 (en) | 1997-10-31 | 1999-08-12 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
| CO5021134A1 (es) * | 1998-05-01 | 2001-03-27 | Abbott Lab | Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina |
| WO1999057098A2 (en) | 1998-05-01 | 1999-11-11 | Abbott Laboratories | Substituted beta-amino acid inhibitors of methionine aminopeptidase-2 |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| AU3733399A (en) | 1998-05-22 | 1999-12-13 | Daiichi Pharmaceutical Co., Ltd. | Drug composites |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| CN1191093C (zh) | 1998-10-30 | 2005-03-02 | 第一制药株式会社 | Dds化合物及其测定方法 |
| JP4883515B2 (ja) | 1999-09-08 | 2012-02-22 | ポリセリックス リミテッド | 均一分子量ポリマー |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
| US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| ATE440094T1 (de) | 2001-09-27 | 2009-09-15 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US20060099660A1 (en) | 2002-02-15 | 2006-05-11 | Synovo Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2003230852B2 (en) | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
| US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| CN102989009B (zh) * | 2003-12-31 | 2015-06-03 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム |
| WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| NZ586125A (en) * | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| WO2009064444A2 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| EP2217283A2 (en) | 2007-11-28 | 2010-08-18 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| JP2011506455A (ja) * | 2007-12-13 | 2011-03-03 | ノバルティス アーゲー | 癌を処置するための治療薬の組み合わせ剤 |
| WO2009141826A2 (en) | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| BR112012016793A2 (pt) | 2010-01-08 | 2018-07-31 | Zafgen Corp | compostos tipo fumagilol e métodos de fazer e usar os mesmos |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| US20130137831A1 (en) | 2010-05-25 | 2013-05-30 | John S. Petersen | Optimized drug conjugates |
| DK2576638T3 (da) | 2010-05-25 | 2021-03-15 | Syndevrx Inc | Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| HUE042801T2 (hu) * | 2010-11-12 | 2019-07-29 | Pharma Mar Sa | Kombinációs terápia mitózisgátlóval |
| WO2012122264A1 (en) | 2011-03-08 | 2012-09-13 | Zafgen Corporation | Oxaspiro [2.5] octane derivatives and analogs |
| US9173956B2 (en) | 2013-04-10 | 2015-11-03 | Syndevrx, Inc. | METAP2 inhibitors and methods of treating obesity |
| ES2900829T3 (es) * | 2013-08-14 | 2022-03-18 | Novartis Ag | Terapia combinada para el tratamiento del cáncer |
| ES2893749T3 (es) | 2015-12-10 | 2022-02-10 | Syndevrx Inc | Derivados de fumagilol y polimorfos de los mismos |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| WO2018027084A2 (en) | 2016-08-03 | 2018-02-08 | Remd Biotherapeutics, Inc. | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer |
| WO2020087077A1 (en) | 2018-10-26 | 2020-04-30 | Syndevrx,Inc. | Biomarkers of metap2 inhibitors and applications thereof |
-
2017
- 2017-01-11 CA CA3008960A patent/CA3008960C/en active Active
- 2017-01-11 KR KR1020187022956A patent/KR20180100663A/ko active Pending
- 2017-01-11 EP EP17701409.9A patent/EP3402529A1/en active Pending
- 2017-01-11 AU AU2017206718A patent/AU2017206718B2/en active Active
- 2017-01-11 JP JP2018536151A patent/JP7022066B2/ja active Active
- 2017-01-11 CA CA3239447A patent/CA3239447A1/en active Pending
- 2017-01-11 WO PCT/US2017/012968 patent/WO2017123603A1/en not_active Ceased
- 2017-01-11 CN CN202111316615.1A patent/CN114225045B/zh active Active
- 2017-01-11 US US15/403,675 patent/US10646463B2/en active Active
- 2017-01-11 CN CN201780016316.1A patent/CN108697807B/zh active Active
- 2017-01-11 MX MX2018008321A patent/MX2018008321A/es unknown
-
2018
- 2018-07-04 MX MX2023002076A patent/MX2023002076A/es unknown
-
2020
- 2020-05-07 US US16/868,693 patent/US11273142B2/en active Active
-
2021
- 2021-12-17 AU AU2021286420A patent/AU2021286420B2/en active Active
-
2022
- 2022-02-04 JP JP2022016251A patent/JP7640481B2/ja active Active
- 2022-03-14 US US17/693,478 patent/US20220280470A1/en active Pending
-
2024
- 2024-06-13 AU AU2024204027A patent/AU2024204027A1/en active Pending
-
2025
- 2025-02-20 JP JP2025025705A patent/JP2025071236A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108697807A (zh) | 2018-10-23 |
| US11273142B2 (en) | 2022-03-15 |
| JP2019501206A (ja) | 2019-01-17 |
| JP2022048388A (ja) | 2022-03-25 |
| CA3239447A1 (en) | 2017-07-20 |
| JP2025071236A (ja) | 2025-05-02 |
| US20210077452A1 (en) | 2021-03-18 |
| AU2024204027A1 (en) | 2024-07-04 |
| CN114225045A (zh) | 2022-03-25 |
| US10646463B2 (en) | 2020-05-12 |
| AU2021286420B2 (en) | 2024-03-14 |
| AU2021286420A1 (en) | 2022-01-20 |
| JP7640481B2 (ja) | 2025-03-05 |
| AU2017206718A1 (en) | 2018-07-05 |
| EP3402529A1 (en) | 2018-11-21 |
| CN114225045B (zh) | 2025-09-26 |
| US20220280470A1 (en) | 2022-09-08 |
| CA3008960C (en) | 2024-07-02 |
| MX2023002076A (es) | 2023-03-17 |
| AU2017206718B2 (en) | 2021-09-30 |
| WO2017123603A1 (en) | 2017-07-20 |
| KR20180100663A (ko) | 2018-09-11 |
| US20170196830A1 (en) | 2017-07-13 |
| JP7022066B2 (ja) | 2022-02-17 |
| CA3008960A1 (en) | 2017-07-20 |
| CN108697807B (zh) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002076A (es) | Conjugado de polimero util para tratar tumores ocasionados por disfuncion metabolica. | |
| PH12019501959A1 (en) | Therapeutic rna | |
| PH12018502429A1 (en) | Antibody molecules for cancer treatment | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2023004221A (es) | Inhibidores de rad51. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| TW201613882A (en) | Histone demethylase inhibitors | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| MY194341A (en) | Method of treating a brain tumor | |
| MX2019001224A (es) | Metodos para tratar el cancer de prostata. | |
| HK1258319A1 (zh) | 癌症疗法 | |
| PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| EA201791814A1 (ru) | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления | |
| PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
| MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
| PH12021551419A1 (en) | New conjugated nucleic acid molecules and their uses | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2020011766A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида | |
| MX2017000087A (es) | Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer. | |
| EA201592012A8 (ru) | Применение флагеллина для улучшенной химиотерапии | |
| MX2020005424A (es) | Composiciones y metodos para terapia contra el cancer. | |
| EA201990411A1 (ru) | Способы лечения рака предстательной железы |